Original citation: J Clin Invest. 2016;126(8):3036–3052. https://doi.org/10.1172/JCI83416
Citation for this expression of concern: J Clin Invest. 2019;129(8):3464 https://doi.org/10.1172/JCI131246
A reader recently alerted the Journal that two images in this JCI article appear similar to images subsequently published in a Neuro-Oncology paper from the same lab as unique samples (1). Specifically, in Figure 9D of the JCI paper, the image for IL13Rα2 staining for the HER2 CAR sample appears to be similar to the image for EphA2 staining of a nontransduced T cell–treated sample published in Figure 6A of the Neuro-Oncology paper. In addition, in Figure 9D of the JCI paper, the image for IL13Rα2 staining for the tumor sample appears to be similar to the image for HER2 staining of a nontransduced T cell–treated sample in Figure 6B of the Neuro-Oncology paper. An institutional investigation into this matter is ongoing, and we will inform our readers of the outcome when the investigation is complete.
Version 1. 07/02/2019
Electronic publication
Version 2. 08/01/2019
Print issue publication
Footnotes
See the related article at Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.
References
- 1.Bielamowicz K, et al. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro Oncol. 2018;20(4):506–518. doi: 10.1093/neuonc/nox182. [DOI] [PMC free article] [PubMed] [Google Scholar]